Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at World Conference on Lung Cancer

Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR -Mutated NSCLC

CARVYKTI_US-SR-10459

Tremfya Dossier Update- bottom

Lazcluze Dossier Update - bottom

Talvey Digital Dossier banner

CARVYKTI_US-SR-10545

Imaavy Dossier banner

Test-EL

Externally Sponsored Scientific Research

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

Product Resources

rybrevant

Dark Blue

oncology

validation-analysis-of-met-ihc-video

Whitelist Modal

Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR -Mutated NSCLC

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join